About Dapagliflozin (Propanediol Monohydrate) API
Categoría Terapéutica Anti-diabético
Número CAS
461432-26-8
Tecnología del API
Sintética
Forma de Dosificación
Tabletas
Estado de Desarrollo en Dr. Reddy’s
Disponible
Presentación Regulatoria Disponible
Singapore DMF, Europe (CEP), USDMF, DMF de Taiwán
Mechanism of Action
Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion
Indication
FARXIGA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related APIs
Empagliflozin
Anti-diabético
Sitagliptin Phosphate (Monohydrate)
Anti-diabético
Sitagliptin Phosphate (Anhydrous)
Anti-diabético
Clorhidrato De Sitagliptina
Anti-diabético
Semaglutide
Anti-diabético
Pioglitazona Clorhidrato
Anti-diabético
Dapagliflozina (amorfa)
Anti-diabético
Dapagliflozin (Propanediol Monohydrate)
Anti-diabético
Glimepirida
Anti-diabético
Linagliptina (Mix of Form A and B)
Anti-diabético
Liraglutida
Anti-diabético